Moderna stock rises on early-stage hantavirus vaccine research with U.S. Army and Korean university.

Moderna's Q2 report expected uneventful; key focus on COVID vaccine demand and Phase III melanoma data.

Moderna is set to report its Q2 results on July 31, with expectations of a modest revenue decline due to seasonal COVID-19 vaccine demand. Jefferies forecasts a loss of $1.99 per share on about $100 million revenue, down from Q1's $389 million. Inves...